Both the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch
Pharmacogenetics Working Group provide therapeutic recommendations for wellknown …

Over the past decade, pharmacogenetic testing has emerged in clinical practice to guide
selected cardiovascular therapies. The most common implementation in practice is …

This document is an update to the 2011 Clinical Pharmacogenetics Implementation
Consortium (CPIC) guideline for CYP2C9 and VKORC1 genotypes and warfarin dosing …

CYP2C9 is the most abundant CYP2C subfamily enzyme in human liver and the most
important contributor from this subfamily to drug metabolism. Polymorphisms resulting in …

Summary Background VKORC1 and CYP2C9 are important contributors to warfarin dose
variability, but explain less variability for individuals of African descent than for those of …

The goals of the Association for Molecular Pathology Pharmacogenomics (PGx) Working
Group of the Association for Molecular Pathology Clinical Practice Committee are to define …

The past decade has seen tremendous advances in our understanding of the genetic factors
influencing response to a variety of drugs, including those targeted at treatment of …

Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of
endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four …

Warfarin is the most commonly used oral anticoagulant in subSaharan Africa. Dosing is
challenging due to a narrow therapeutic index and high interindividual variability in dose …

Highlights•The interindividual variability of CYP2C members and its impact in drug
metabolism are reviewed.•Current advances in molecular modeling of CYP2C …